Basis: Latest reported fiscal year. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -114.70% is 170% below its 5-year average of 164.66%, near the low end of its 5-year range (-114.70%–773.06%).
As of the fiscal period ended Wednesday, December 31, 2025. 134.84% below its 12-month average of 329.18%.
Annual fiscal-year return on equity; no daily interpolation.
RETURN ON EQUITY (ROE)
-114.70%
RETURN ON EQUITY (ROE) AVG TTM
329.18%
RETURN ON EQUITY (ROE) AVG 3Y
200.63%
RETURN ON EQUITY (ROE) AVG 5Y
164.66%
RETURN ON EQUITY (ROE) AVG 10Y
97.17%
RETURN ON EQUITY (ROE) AVG 15Y
28.18%
RETURN ON EQUITY (ROE) AVG 20Y
23.46%
CURRENT VS TTM AVG
-134.84%
CURRENT VS 3Y AVG
-157.17%
CURRENT VS 5Y AVG
-169.66%
CURRENT VS 10Y AVG
-218.04%
CURRENT VS 15Y AVG
-507.00%
CURRENT VS 20Y AVG
-588.92%
SECTOR MEDIAN · HEALTHCARE
10.89%
median of 79 covered companies
CURRENT VS SECTOR MEDIAN
-1153.26%
vs the sector median at left
DaVita Inc.
Market Cap
$15.47B
Return on Equity (ROE)
-114.70%
TTM Avg
329.18%
3Y Avg
200.63%
5Y Avg
164.66%
Market Cap
$15.33B
Return on Equity (ROE)
28.82%
TTM Avg
23.51%
3Y Avg
17.50%
5Y Avg
13.68%
Market Cap
$16.33B
Return on Equity (ROE)
113.29%
TTM Avg
73.63%
3Y Avg
65.34%
5Y Avg
49.74%
Market Cap
$14.25B
Return on Equity (ROE)
2.86%
TTM Avg
4.70%
3Y Avg
4.67%
5Y Avg
11.22%
Market Cap
$16.97B
Return on Equity (ROE)
10.37%
TTM Avg
13.30%
3Y Avg
15.60%
5Y Avg
24.66%
Market Cap
$12.90B
Return on Equity (ROE)
9.77%
TTM Avg
10.54%
3Y Avg
10.84%
5Y Avg
19.93%
Market Cap
$12.79B
Return on Equity (ROE)
-18.17%
TTM Avg
-12.46%
3Y Avg
-8.76%
5Y Avg
-1.37%
Market Cap
$12.65B
Return on Equity (ROE)
3.35%
TTM Avg
3.59%
3Y Avg
3.35%
5Y Avg
7.68%
Market Cap
$18.79B
Return on Equity (ROE)
6.01%
TTM Avg
6.40%
3Y Avg
5.73%
5Y Avg
4.16%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| DaVita Inc. (DVA) | $15.47B | -114.70% | 329.18% | 200.63% | 164.66% |
| Solventum Corporation (SOLV)vs › | $15.33B | 28.82% | 23.51% | 17.50% | 13.68% |
| Medpace Holdings, Inc. (MEDP)vs › | $16.33B | 113.29% | 73.63% | 65.34% | 49.74% |
| The Cooper Companies, Inc. (COO)vs › | $14.25B | 2.86% | 4.70% | 4.67% | 11.22% |
| Hologic, Inc. (HOLX)vs › | $16.97B | 10.37% | 13.30% | 15.60% | 24.66% |
| Align Technology, Inc. (ALGN)vs › | $12.90B | 9.77% | 10.54% | 10.84% | 19.93% |
| Baxter International Inc. (BAX)vs › | $12.79B | -18.17% | -12.46% | -8.76% | -1.37% |
| Revvity, Inc. (RVTY)vs › | $12.65B | 3.35% | 3.59% | 3.35% | 7.68% |
| Zimmer Biomet Holdings, Inc. (ZBH)vs › | $18.79B | 6.01% | 6.40% | 5.73% | 4.16% |
| Insulet Corp. (PODD)vs › | $11.82B | 23.25% | 25.41% | 19.99% | 14.02% |
ROE
-114.7%
ROA
4.5%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2025-12-31 | -114.70% |
| 2024-12-31 | 773.06% |
| 2023-12-31 | 65.48% |
| 2022-12-31 | 78.67% |
| 2021-12-31 | 129.51% |
| 2020-12-31 | 55.92% |
| 2019-12-31 | 38.01% |
| 2018-12-31 | 4.30% |
| 2017-12-31 | 14.15% |
| 2016-12-31 | 18.93% |
| 2015-12-31 | 5.54% |
| 2014-12-31 | 13.99% |
| 2013-12-31 | 14.29% |
| 2012-12-31 | 14.24% |
| 2011-12-31 | 22.33% |
| 2010-12-31 | 20.51% |
| 2009-12-31 | 19.80% |
| 2008-12-31 | 19.16% |
| 2007-12-31 | 22.04% |
| 2006-12-31 | 23.25% |
| 2005-12-31 | 26.88% |
| 2004-12-31 | 42.49% |
| 2003-12-31 | 57.28% |
| 2002-12-31 | 223.91% |
| 2001-12-31 | 27.26% |
| 2000-12-31 | 3.86% |
| 1999-12-31 | -45.11% |
| 1998-12-31 | -1.95% |
| 1997-12-31 | 16.62% |
| 1996-12-31 | 11.56% |
